Search Within

Matthew David Hellmann

  1. "Meeting abstract"
Formats
  1. Meeting Abstract (210)
Groups
  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (210)
  3. Thoracic Oncology (210)
  4. GSK Faculty (59)
  5. Department of Pathology and Laboratory Medicine (50)
  6. Weinberg Fellows (43)

More Groups

People
  1. Hira Rizvi (46)
  2. Mark Kris (31)
  3. Charles Rudin (27)
  4. Jamie Chaft (27)
  5. Jedd Wolchok (21)
  6. Kathryn Arbour (20)

More People

Years
  1. 2023 (4)
  2. 2022 (10)
  3. 2021 (21)
  4. 2020 (27)
  5. 2019 (30)
  6. 2018 (49)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (40)
  3. Annals of Oncology (23)
  4. Cancer Research (22)
  5. Journal for ImmunoTherapy of Cancer (19)
  6. Oncology Research and Treatment (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (75)
  2. Elsevier Inc. (47)
  3. American Association for Cancer Research (24)
  4. Oxford University Press (24)
  5. Biomed Central Ltd (19)
  6. S. Karger AG (9)

More Publishers

Results (210)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genome-scale neoantigen screening using ATLAS™ prioritizes candidates for immunotherapy in a non-small cell lung cancer patient
    Meeting Abstract

    Ghamsari, L.; Flano, E.; Jacques, J.; Liu, B.; Havel, J.; Makarov, V.; Merghoub, T.; Wolchok, J. D.; Hellmann, M. D.; Chan, T. A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Opposing effects of CTLA-4 and PD-1 blockade on follicular helperlike T cells with immunosuppressive functions
    Meeting Abstract

    Zappasodi, R.; Budhu, S.; Hellmann, M. D.; Postow, M.; Senbabaoglu, Y.; Gasmi, B.; Zhong, H.; Li, Y.; Liu, C.; Hirschhorhn-Cymerman, D.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Johnson, M. L.; Adjei, A. A.; Opyrchal, M.; Ramalingam, S.; Janne, P. A.; Dominguez, G.; Gabrilovich, D.; de Leon, L.; Hasapidis, J.; Diede, S. J.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
    Meeting Abstract

    Kowanetz, M.; Zou, W.; Shames, D. S.; Cummings, C.; Rizvi, N.; Spira, A. I.; Frampton, G. M.; Leveque, V.; Flynn, S.; Mocci, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
    Meeting Abstract

    Forde, P. M.; Smith, K. N.; Chaft, J. E.; Hellmann, M.; Merghoub, T.; Wolchok, J. D.; Yang, S. C.; Battafarano, R. J.; Gabrielson, E.; Georgiades, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung)
    Meeting Abstract

    Fracasso, P. M.; Freeman, D. J.; Simonsen, K.; Shen, Y.; Gupta, M.; Comprelli, A.; Gainor, J. F.; Hellmann, M.; Chow, L. Q.; Forde, P. M.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Long-term outcomes with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
    Meeting Abstract

    Barlesi, F.; Steins, M.; Horn, L.; Ready, N.; Felip, E.; Borghaei, H.; Spigel, D. R.; Arrieta, O.; Antonia, S. J.; Fayette, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Meeting Abstract

    Eberhardt, W. E. E.; Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab
    Meeting Abstract

    Voss, M. H.; Hellmann, M. D.; Chen, Y.; Gold, T. M.; Lambert, C. R.; VanAllen, E.; Choueiri, T. K.; Charen, A. S.; Motzer, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kowanetz, M.; Koeppen, H.; Zou, W.; Mariathasan, S.; Hellmann, M.; Kockx, M.; Chappey, C.; Kadel, E.; Smith, D.; Miley, N.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save